ArticleGenes & genomics2025
NCOA4 inhibits glioma progression by suppressing the Sonic Hedgehog pathway and its overexpression indicates a better glioma prognosis.
Article in Genes & genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundNuclear receptor coactivator 4 (NCOA4) is known to be involved in ferroptosis. However, its expression and function in gliomas are still unclear.
objectiveTo assess the expression of NCOA4 in gliomas and explore the mechanisms by which NCOA4 affects glioma progression.
methodsRNA-seq data for glioma patient tissues and normal brain tissues were obtained from The Cancer Genome Atlas and the Genotype Tissue Expression project. NCOA4 expression was assessed by Western blotting (WB) and immunohistochemistry (IHC). Overexpression and knockdown of NCOA4 were induced in glioma cell lines via transduction of recombinant adenovirus encoding NCOA4 and NCOA4 siRNA, respectively. Cell Counting Kit-8 (CCK-8), Transwell and flow cytometry assays were performed to assess cell proliferation, invasion and apoptosis.
resultsWB and IHC revealed that NCOA4 was markedly downregulated in glioma cell lines and human specimens compared to controls, and high NCOA4 expression was associated with a better glioma prognosis. NCOA4 overexpression inhibited glioma cell growth and invasion and induced apoptosis, whereas NCOA4 knockdown promoted glioma cell growth. PTCH1 was predicted to interact with NCOA4 via bioinformatics analysis. NCOA4 overexpression increased the expression of PTCH1 and suppressed the expression of SMO, Bcl-2 and the nuclear translocation of Gli1, indicating that NCOA4 suppresses the SHH pathway. PTCH1 knockdown reversed the inhibitory effects of NCOA4 on the malignant behaviours of glioma cells.
conclusionsThese results suggest that NCOA4 is downregulated in gliomas and that its overexpression predicts better overall survival in glioma patients. Mechanistically, NCOA4 overexpression inhibits the progression of glioma by suppressing the SHH pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.